Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could centralized surgery boost ovarian cancer survival?

NCT ID NCT07075939

Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian cancer between 2018 and 2023, tracking their treatments and outcomes for up to five years. The goal is to understand which care strategies lead to better survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it works, this could point toward better ways to organize ovarian cancer care to improve survival.
What could go wrong
This is an observational study, so it can show links but not prove cause and effect. Results may be affected by differences in patient groups or care outside the study network.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women diagnosed with epithelial ovarian cancer between January 2018 and December 2023, treated in the REMO oncological network (Reggio Emilia and Modena, Italy). Patients will be identified through retrospective review of clinical records and prospective follow-up data.

Ages

18 to 99 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged between 18 and 99 years * Histological and/or cytological diagnosis of epithelial ovarian cancer * Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia * Patients treated between January 1, 2018, and December 31, 2023 * Availability of clinical records and outcome data * Signed informed consent where possible, in accordance with GDPR and Italian regulations Exclusion Criteria: * Patients without histological or cytological confirmation of epithelial ovarian cancer * Incomplete or missing data for key clinical indicators * Patients unable to provide informed consent and for whom recontact is not possible * Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial COVID-19 ovarian cancer ovarian carcinoma ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced ovarian cancer Epithelial ovarian cancer Ovarian neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliero - Universitario di Modena

    RECRUITING

    Modena, Italy

  • Azienda USL IRCCS di Reggio Emilia

    RECRUITING

    Reggio Emilia, RE, 42123, Italy

  • Azienda Unità - Sanitaria locale di Modena - Ospedale Civile Sassuolo

    RECRUITING

    Sassuolo, Modena, Italy

  • Azienda Unità - Sanitaria locale di Modena - Ospedale Pavullo nel Frignano

    NOT_YET_RECRUITING

    Pavullo nel Frignano, Modena, Italy

  • Azienda Unità - Sanitaria locale di Modena - Ospedale Razzini Carpi

    RECRUITING

    Carpi, Modena, Italy

  • Azienda Unità - Sanitaria locale di Modena - Ospedale di Mirandola

    RECRUITING

    Mirandola, Modena, Italy

  • Azienda Unità - Sanitaria locale di Modena - Ospedale di Vignola

    NOT_YET_RECRUITING

    Vignola, Modena, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.